ClinicalTrials.gg
TerminatedNCT02393248Updated Jan 6, 2023Results posted

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

A Phase 1/2 interventional study of Pemigatinib and Gemcitabine in Lung Cancer, Solid Tumor and Gastric Cancer, sponsored by Incyte Corporation. Terminated at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-06.

Sponsored by Incyte Corporation · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
201
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Lung Neoplasms by Incyte Corporation — none open to participants now, 1 under way, none of them phase 3. Lung Neoplasms · Incyte Corporation.

Enrollment
5th of 11
201 · median 176
Started
2015
with 1 other
Phase 1/2
5 of 11
none open now
Registered
4th of 11
by date

Among the 11 studies in Lung Neoplasms by Incyte Corporation, this one is the 5th largest by enrollment, is one of 2 that started in 2015, is one of 5 in phase 1/2, and was the 4th registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

None of the 11 studies in Lung Neoplasms by Incyte Corporation is open now. The open studies under Lung Neoplasms, anywhere →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Lung Neoplasms by Incyte Corporation as a file.
02

Study summary

The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies. This study will have three parts, dose escalation (Part 1), dose expansion (Part 2) and combination therapy (Part 3).

03

Conditions studied

  • Lung Cancer
  • Solid Tumor
  • Gastric Cancer
  • Urothelial Cancer
  • Endometrial Cancer
  • Multiple Myeloma
  • Myeloproliferative Neoplasms
  • Breast Cancer
  • Cholangiocarcinoma
  • UC
  • MPN

Keywords

  • alterations in FGF or FGFR
  • squamous non-small cell lung cancer
  • gastric cancer
  • urothelial cancer
  • endometrial cancer
  • multiple myeloma
  • MPN
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects, age 18 years or older on day of signing consent
  2. Part 1: Any advanced solid tumor ; Part 2: Subjects with squamous non-small cell lung cancer, cholangiocarcinoma/gastric cancer, urothelial cancer, breast/endometrial cancer, multiple myeloma, or MPNs that have a tumor or malignancy that has been evaluated and confirmed to harbor genetic alterations in FGF or FGFR genes. A subject's fibroblast growth factor (FGF) or fibroblast growth factor receptor (FGFR) alteration may be based on local or central laboratory results. Part 3: Dose finding: subjects with solid tumor malignancies who qualify for combo therapy; dose-expansion: FGF/FGFR+ subjects qualified to receive combo therapy
  3. Has progressed after prior therapy and there is no further effective standard anticancer therapy available (including subject refuses or is intolerant)
  4. > 12 weeks
  5. (ECOG) performance status:

    • Part 1: 0 or 1
    • Part 2 and 3: 0, 1, or 2

Exclusion criteria

Exclusion Criteria:

  1. Treatment with other study drug for any indication for any reason, or receipt of anticancer medications within 21 days or 5 half-lives before first dose of study drug
  2. Prior receipt of a selective FGFR inhibitor
  3. History of a calcium/phosphate homeostasis disorder
  4. History and/or current evidence of ectopic mineralization/calcification
  5. Current evidence of corneal disorder/keratopathy
  6. Has a history or presence of inadequate liver, renal, hematopoietic and/or cardiac function parameters outside protocol-defined range
  7. Prior radiotherapy within 2 weeks of study treatment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    Part 1: Intermittent pemigatinib 1/2/4 mg QD

    Participants self-administered oral pemigatinib 1/2/4 milligrams (mg) once daily (QD) on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

    Drug: Pemigatinib

  • Experimental
    Part 1: Intermittent pemigatinib 6 mg QD

    Participants self-administered oral pemigatinib 6 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

    Drug: Pemigatinib

  • Experimental
    Part 1: Intermittent pemigatinib 9 mg QD

    Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

    Drug: Pemigatinib

  • Experimental
    Part 1: Intermittent pemigatinib 13.5 mg QD

    Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

    Drug: Pemigatinib

  • Experimental
    Part 1: Intermittent pemigatinib 20 mg QD

    Participants self-administered oral pemigatinib 20 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

    Drug: Pemigatinib

  • Experimental
    Part 1: Continuous pemigatinib 9 mg QD

    Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle.

    Drug: Pemigatinib

  • Experimental
    Part 1: Continuous pemigatinib 13.5 mg QD

    Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.

    Drug: Pemigatinib

  • Experimental
    Part 1: Continuous pemigatinib 20 mg QD

    Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle.

    Drug: Pemigatinib

  • Experimental
    Part 1: Continuous pemigatinib 7.5 mg BID

    Participants self-administered oral pemigatinib 7.5 mg twice daily (BID) on Days 1 through 21 of each 21-day cycle.

    Drug: Pemigatinib

  • Experimental
    Part 1: Continuous pemigatinib 10 mg BID

    Participants self-administered oral pemigatinib 10 mg BID on Days 1 through 21 of each 21-day cycle.

    Drug: Pemigatinib

  • Experimental
    Part 2: Intermittent pemigatinib 9 mg QD

    Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

    Drug: Pemigatinib

  • Experimental
    Part 2: Intermittent pemigatinib 13.5 mg QD

    Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

    Drug: Pemigatinib

  • Experimental
    Part 2: Continuous pemigatinib 9 mg QD

    Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle.

    Drug: Pemigatinib

  • Experimental
    Part 2: Continuous pemigatinib 13.5 mg QD

    Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.

    Drug: Pemigatinib

  • Experimental
    Part 2: Continuous pemigatinib 20 mg QD

    Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle.

    Drug: Pemigatinib

  • Experimental
    Part 3: Gem/Cis/intermittent pemigatinib 9 mg

    Participants received gemcitabine (Gem) intravenously starting at 1000 mg/meters squared (m\^2) (30 minutes) on Days 1 and 8 of each 21-day cycle. Cisplatin (Cis) was administered intravenously starting at 70 mg/m\^2 (1-4 hours) once every 3 weeks on Day 1 of each 21-day cycle. Both gemcitabine and cisplatin doses could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of gemcitabine/cisplatin.

    Drug: Pemigatinib · Drug: Gemcitabine · Drug: Cisplatin

  • Experimental
    Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg

    Participants received gemcitabine intravenously starting at 1000 mg/m\^2 (30 minutes) on Days 1 and 8 of each 21-day cycle. Cisplatin was administered intravenously starting at 70 mg/m\^2 (1-4 hours) once every 3 weeks on Day 1 of each 21-day cycle. Both gemcitabine and cisplatin doses could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of gemcitabine/cisplatin.

    Drug: Pemigatinib · Drug: Gemcitabine · Drug: Cisplatin

  • Experimental
    Part 3: Tras/intermittent pemigatinib 13.5 mg

    Trastuzumab (Tras) was administered as an open-label, commercial product at an initial dose of 8 mg/kilograms (kg) over a 90-minute intravenous infusion, followed by 6 mg/kg over a 30- to 90-minute intravenous infusion once every 3 weeks. The dose could have been adjusted for toxicity management, per commercial labeling. The investigator could have interrupted, modified, or discontinued trastuzumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of trastuzumab.

    Drug: Pemigatinib · Drug: Trastuzumab

  • Experimental
    Part 3: Doc/intermittent pemigatinib 13.5 mg

    Participants received docetaxel (Doc) intravenously starting at 75 mg/m\^2 (1 hour) once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of docetaxel.

    Drug: Pemigatinib · Drug: Docetaxel

  • Experimental
    Part 3: Pem/intermittent pemigatinib 9 mg

    Participants received pembrolizumab (Pem) intravenously at 200 mg (30 minutes) once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.

    Drug: Pemigatinib · Drug: Pembrolizumab

  • Experimental
    Part 3: Pem/intermittent pemigatinib 13.5 mg

    Participants received pembrolizumab intravenously at 200 mg (30 minutes) once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.

    Drug: Pemigatinib · Drug: Pembrolizumab

  • Experimental
    Part 3: Pem/continuous pemigatinib 13.5 mg

    Participants received pembrolizumab intravenously at 200 mg (30 minutes) once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.

    Drug: Pemigatinib · Drug: Pembrolizumab

  • Experimental
    Part 3: Ref/continuous pemigatinib 9 mg

    Retifanlimab (Ref) was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial dose of 500 mg over a 60-minute intravenous infusion. Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle.

    Drug: Pemigatinib · Drug: Retifanlimab

  • Experimental
    Part 3: Ref/continuous pemigatinib 13.5 mg

    Retifanlimab was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial dose of 500 mg over a 60-minute intravenous infusion. Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.

    Drug: Pemigatinib · Drug: Retifanlimab

  • Experimental
    Part 3: Ref/continuous pemigatinib 20 mg

    Retifanlimab was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial dose of 500 mg over a 60-minute intravenous infusion. Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle.

    Drug: Pemigatinib · Drug: Retifanlimab

Interventions

06

What researchers measure

Primary outcomes

  1. Parts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    Adverse events were defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after a participant provided informed consent. Abnormal laboratory values or test results that occurred after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). TEAEs were defined as adverse events either reported for the first time or the worsening of pre-existing events after the first dose of study drug and within 30 days of the last dose of study drug.

    Time frame: up to 763 days

  2. Part 3: Number of Participants With Any TEAE

    Adverse events were defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after a participant provided informed consent. Abnormal laboratory values or test results that occurred after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). TEAEs were defined as adverse events either reported for the first time or the worsening of pre-existing events after the first dose of study drug and within 30 days of the last dose of study drug.

    Time frame: up to 869 days

  3. E0 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2

    E0 was defined as the Baseline serum concentration of phosphate.

    Time frame: predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles

  4. EC50 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2

    EC50 was defined as the pemigatinib steady-state area under the plasma or serum concentration-time curve that increases 50% of serum phosphate.

    Time frame: predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles

  5. Emax Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2

    Emax was defined as the maximum degree of increasing of serum phosphate by pemigatinib.

    Time frame: predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles

  6. Highest Serum Phosphate Concentration Following Pemigatinib as Monotherapy in Parts 1 and 2

    Serum phosphate concentration was assessed throughout Parts 1 and 2.

    Time frame: predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles

Secondary outcomes

  1. Part 2: Overall Response Rate (ORR)

    ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as determined by the investigator. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.

    Time frame: up to 126 days

  2. Part 3: ORR

    ORR was defined as the percentage of participants with a best overall response of CR or PR, per RECIST version 1.1, as determined by the investigator. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.

    Time frame: up to 203 days

  3. Parts 1 and 2: Cmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1

    Cmax was defined as the maximum observed plasma concentration.

    Time frame: Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1

  4. Parts 1 and 2: Tmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1

    tmax was defined as the time to the maximum observed plasma concentration.

    Time frame: Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1

  5. Parts 1 and 2: AUClast After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1

    AUClast was defined as the area under the plasma or serum concentration-time curve from the time of dosing to the last measurable concentration.

    Time frame: Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1

  6. Parts 1 and 2: AUC0-24 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1

    AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.

    Time frame: Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1

  7. Parts 1 and 2: Cmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

    Cmax was defined as the maximum observed plasma concentration.

    Time frame: Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

  8. Parts 1 and 2: Tmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

    tmax was defined as the time to the maximum observed plasma concentration.

    Time frame: Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

  9. Parts 1 and 2: t1/2 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

    t1/2 was defined as the apparent plasma terminal phase disposition half-life.

    Time frame: Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

  10. Parts 1 and 2: Cmin After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

    Cmin was defined as the minimum observed plasma concentration over the dose interval.

    Time frame: Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

  11. Parts 1 and 2: AUC0-24 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

    AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.

    Time frame: Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

  12. Parts 1 and 2: CL/F After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

    CL/F was defined as the apparent oral dose clearance.

    Time frame: Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

  13. Parts 1 and 2: Vz/F After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

    Vz/F was defined as the apparent volume of distribution.

    Time frame: Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

  14. Parts 1 and 2: Accumulation Ratio After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

    The accumulation ratio was defined as the ratio of the accumulation of a drug under steady-state conditions as compared to a single dose.

    Time frame: Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

  15. Parts 1 and 2: Cmax Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States

    Cmax was defined as the maximum observed plasma concentration.

    Time frame: Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14

  16. Parts 1 and 2: Tmax Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States

    tmax was defined as the time to the maximum observed plasma concentration.

    Time frame: Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14

  17. Parts 1 and 2: t1/2 Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States

    t1/2 was defined as the apparent plasma terminal phase disposition half-life.

    Time frame: Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14

  18. Parts 1 and 2: Cmin Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States

    Cmin was defined as the minimum observed plasma concentration over the dose interval.

    Time frame: Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14

  19. Parts 1 and 2: AUC0-24 Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States

    AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.

    Time frame: Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14

  20. Parts 1 and 2: CL/F Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States

    CL/F was defined as the apparent oral dose clearance.

    Time frame: Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14

  21. Parts 1 and 2: Vz/F Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States

    Vz/F was defined as the apparent volume of distribution.

    Time frame: Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14

  22. Part 3: Cmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1

    Cmax was defined as the maximum observed plasma concentration.

    Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 1

  23. Part 3: Tmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1

    tmax was defined as the time to the maximum observed plasma concentration.

    Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 1

  24. Part 3: AUClast of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1

    AUClast was defined as the area under the plasma or serum concentration-time curve from the time of dosing to the last measurable concentration.

    Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 1

  25. Part 3: AUC0-24 of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1

    AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.

    Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 1

  26. Part 3: Cmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

    Cmax was defined as the maximum observed plasma concentration.

    Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

  27. Part 3: Tmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

    tmax was defined as the time to the maximum observed plasma concentration.

    Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

  28. Part 3: t1/2 of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

    t1/2 was defined as the apparent plasma terminal phase disposition half-life.

    Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

  29. Part 3: Cmin of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

    Cmin was defined as the minimum observed plasma concentration over the dose interval.

    Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

  30. Part 3: AUC0-24 of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

    AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.

    Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

  31. Part 3: CL/F of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

    CL/F was defined as the apparent oral dose clearance.

    Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

  32. Part 3: Vz/F of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

    Vz/F was defined as the apparent volume of distribution.

    Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

  33. Part 3: Accumulation Ratio of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

    The accumulation ratio was defined as the ratio of the accumulation of a drug under steady-state conditions as compared to a single dose.

    Time frame: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14

07

Results

Posted Jan 6, 2023

Participant flow

This study was conducted at 15 study sites: 14 sites in the United States and 1 site in Denmark. The study was conducted in 3 parts. Participants self-administered once daily doses of pemigatinib on a 2-weeks-on/1-week-off therapy (intermittent) or continuous schedule in 21-day cycles. Participants also self-administered twice daily doses of pemigatinib on a continuous schedule.

Part 1: Monotherapy Dose Escalation
Participant flow — Part 1: Monotherapy Dose Escalation
MilestonePart 1: Intermittent Pemigatinib 1/2/4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDPart 1: Intermittent Pemigatinib 9 mg QDPart 1: Intermittent Pemigatinib 13.5 mg QDPart 1: Intermittent Pemigatinib 20 mg QDPart 1: Continuous Pemigatinib 9 mg QDPart 1: Continuous Pemigatinib 13.5 mg QDPart 1: Continuous Pemigatinib 20 mg QDPart 1: Continuous Pemigatinib 7.5 mg BIDPart 1: Continuous Pemigatinib 10 mg BIDPart 2: Intermittent Pemigatinib 9 mg QDPart 2: Intermittent Pemigatinib 13.5 mg QDPart 2: Continuous Pemigatinib 9 mg QDPart 2: Continuous Pemigatinib 13.5 mg QDPart 2: Continuous Pemigatinib 20 mg QDPart 3: Gem/Cis/Intermittent Pemigatinib 9 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 9 mgPart 3: Ref/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 20 mg
Started34366910943000000000000000
Completed0000001100000000000000000
Not completed3436699843000000000000000
Withdrew: Withdrawal by subject0100011000000000000000000
Withdrew: Disease progression0100000000000000000000000
Withdrew: Death2236665842000000000000000
Withdrew: Lost to follow-up1000000000000000000000000
Withdrew: Study terminated by sponsor0000022001000000000000000
Withdrew: Clinical decline; withdrew by physician0000001000000000000000000
Part 2: Monotherapy Dose Expansion
Participant flow — Part 2: Monotherapy Dose Expansion
MilestonePart 1: Intermittent Pemigatinib 1/2/4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDPart 1: Intermittent Pemigatinib 9 mg QDPart 1: Intermittent Pemigatinib 13.5 mg QDPart 1: Intermittent Pemigatinib 20 mg QDPart 1: Continuous Pemigatinib 9 mg QDPart 1: Continuous Pemigatinib 13.5 mg QDPart 1: Continuous Pemigatinib 20 mg QDPart 1: Continuous Pemigatinib 7.5 mg BIDPart 1: Continuous Pemigatinib 10 mg BIDPart 2: Intermittent Pemigatinib 9 mg QDPart 2: Intermittent Pemigatinib 13.5 mg QDPart 2: Continuous Pemigatinib 9 mg QDPart 2: Continuous Pemigatinib 13.5 mg QDPart 2: Continuous Pemigatinib 20 mg QDPart 3: Gem/Cis/Intermittent Pemigatinib 9 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 9 mgPart 3: Ref/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 20 mg
Started000000000044452060000000000
Completed0000000000000010000000000
Not completed000000000044452050000000000
Withdrew: Withdrawal by subject00000000000131230000000000
Withdrew: Disease progression0000000000110000000000000
Withdrew: Death000000000032941520000000000
Withdrew: Study terminated by sponsor0000000000010300000000000
Part 3: Combination Therapy
Participant flow — Part 3: Combination Therapy
MilestonePart 1: Intermittent Pemigatinib 1/2/4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDPart 1: Intermittent Pemigatinib 9 mg QDPart 1: Intermittent Pemigatinib 13.5 mg QDPart 1: Intermittent Pemigatinib 20 mg QDPart 1: Continuous Pemigatinib 9 mg QDPart 1: Continuous Pemigatinib 13.5 mg QDPart 1: Continuous Pemigatinib 20 mg QDPart 1: Continuous Pemigatinib 7.5 mg BIDPart 1: Continuous Pemigatinib 10 mg BIDPart 2: Intermittent Pemigatinib 9 mg QDPart 2: Intermittent Pemigatinib 13.5 mg QDPart 2: Continuous Pemigatinib 9 mg QDPart 2: Continuous Pemigatinib 13.5 mg QDPart 2: Continuous Pemigatinib 20 mg QDPart 3: Gem/Cis/Intermittent Pemigatinib 9 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 9 mgPart 3: Ref/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 20 mg
Started00000000000000017673149792
Completed0000000000000000000000011
Not completed00000000000000017673149781
Withdrew: Withdrawal by subject0000000000000000001021010
Withdrew: Death0000000000000001755375630
Withdrew: Study terminated by sponsor0000000000000000011011121
Withdrew: Disease progression0000000000000000000021000
Withdrew: Lost to follow-up0000000000000000000011000
Withdrew: Rolled over to another protocol after receiving same treatment0000000000000000000010000
Withdrew: Adverse event0000000000000000000000010
Withdrew: Placed on hospice; declined further follow-up0000000000000000000000010

Outcome measures

PrimaryParts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

Adverse events were defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after a participant provided informed consent. Abnormal laboratory values or test results that occurred after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). TEAEs were defined as adverse events either reported for the first time or the worsening of pre-existing events after the first dose of study drug and within 30 days of the last dose of study drug.

Time frame:
up to 763 days
Reported as:
Count of participants · Participants
Parts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
ParticipantsPart 1: Intermittent Pemigatinib 1/2/4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDParts 1 and 2: Intermittent Pemigatinib 9 mg QDParts 1 and 2: Intermittent Pemigatinib 13.5 mg QDPart 1: Intermittent Pemigatinib 20 mg QDParts 1 and 2: Continuous Pemigatinib 9 mg QDParts 1 and 2: Continuous Pemigatinib 13.5 mg QDParts 1 and 2: Continuous Pemigatinib 20 mg QDPart 1: Continuous Pemigatinib 7.5 mg BIDPart 1: Continuous Pemigatinib 10 mg BID
Parts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)33750614301543
PrimaryPart 3: Number of Participants With Any TEAE

Adverse events were defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after a participant provided informed consent. Abnormal laboratory values or test results that occurred after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). TEAEs were defined as adverse events either reported for the first time or the worsening of pre-existing events after the first dose of study drug and within 30 days of the last dose of study drug.

Time frame:
up to 869 days
Reported as:
Count of participants · Participants
Part 3: Number of Participants With Any TEAE
ParticipantsPart 3: Gem/Cis/Intermittent Pemigatinib 9 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 9 mgPart 3: Ref/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 20 mg
Part 3: Number of Participants With Any TEAE17673149792
PrimaryE0 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2

E0 was defined as the Baseline serum concentration of phosphate.

Time frame:
predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles
Reported as:
Geometric mean · milligrams per deciliter (mg/dL)
E0 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2
milligrams per deciliter (mg/dL)Parts 1 and 2: Intermittent or Continuous Pemigatinib
E0 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 23.66 ± 1.91
PrimaryEC50 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2

EC50 was defined as the pemigatinib steady-state area under the plasma or serum concentration-time curve that increases 50% of serum phosphate.

Time frame:
predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles
Reported as:
Geometric mean · hours*nanomoles
EC50 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2
hours*nanomolesParts 1 and 2: Intermittent or Continuous Pemigatinib
EC50 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 21573 ± 21.6
PrimaryEmax Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2

Emax was defined as the maximum degree of increasing of serum phosphate by pemigatinib.

Time frame:
predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles
Reported as:
Geometric mean · mg/dL
Emax Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2
mg/dLParts 1 and 2: Intermittent or Continuous Pemigatinib
Emax Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 25.76 ± 7.76
PrimaryHighest Serum Phosphate Concentration Following Pemigatinib as Monotherapy in Parts 1 and 2

Serum phosphate concentration was assessed throughout Parts 1 and 2.

Time frame:
predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles
Reported as:
Number · mg/dL
Highest Serum Phosphate Concentration Following Pemigatinib as Monotherapy in Parts 1 and 2
mg/dLParts 1 and 2: Intermittent or Continuous Pemigatinib
Minimum value in range of highest values for all participants3.5
Maximum value in range of highest values for all participants11.2
SecondaryPart 2: Overall Response Rate (ORR)

ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as determined by the investigator. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.

Time frame:
up to 126 days
Reported as:
Number · percentage of participants
Part 2: Overall Response Rate (ORR)
percentage of participantsPart 2: Intermittent Pemigatinib 9 mg QDPart 2: Intermittent Pemigatinib 13.5 mg QDPart 2: Continuous Pemigatinib 9 mg QDPart 2: Continuous Pemigatinib 13.5 mg QDPart 2: Continuous Pemigatinib 20 mg QD
Part 2: Overall Response Rate (ORR)25.0 (0.6 to 80.6)4.5 (0.6 to 15.5)0.0 (0.0 to 52.2)30.0 (11.9 to 54.3)0.0 (0.0 to 45.9)
SecondaryPart 3: ORR

ORR was defined as the percentage of participants with a best overall response of CR or PR, per RECIST version 1.1, as determined by the investigator. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.

Time frame:
up to 203 days
Reported as:
Number · percentage of participants
Part 3: ORR
percentage of participantsPart 3: Gem/Cis/Intermittent Pemigatinib 9 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 9 mgPart 3: Ref/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 20 mg
Part 3: ORR0.0 (0.0 to 97.5)42.9 (9.9 to 81.6)0.0 (0.0 to 45.9)14.3 (0.4 to 57.9)0.0 (0.0 to 70.8)28.6 (8.4 to 58.1)33.3 (7.5 to 70.1)0.0 (0.0 to 41.0)22.2 (2.8 to 60.0)0.0 (0.0 to 84.2)
SecondaryParts 1 and 2: Cmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1

Cmax was defined as the maximum observed plasma concentration.

Time frame:
Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1
Reported as:
Mean · nanograms per milliliter (ng/mL)
Parts 1 and 2: Cmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1
nanograms per milliliter (ng/mL)Part 1: Intermittent Pemigatinib 1 mg QDPart 1: Intermittent Pemigatinib 2 mg QDPart 1: Intermittent Pemigatinib 4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD
Parts 1 and 2: Cmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 125.3 ± NA13.6 ± NA109 ± NA64.6 ± 9.16139 ± 79.8196 ± 121300 ± 135
SecondaryParts 1 and 2: Tmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1

tmax was defined as the time to the maximum observed plasma concentration.

Time frame:
Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1
Reported as:
Median · hours (hr)
Parts 1 and 2: Tmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1
hours (hr)Part 1: Intermittent Pemigatinib 1 mg QDPart 1: Intermittent Pemigatinib 2 mg QDPart 1: Intermittent Pemigatinib 4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD
Parts 1 and 2: Tmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 11 (NA to NA)5.92 (NA to NA)2.02 (NA to NA)1.14 (1.00 to 2.08)1.17 (0.500 to 2.13)1.20 (0.400 to 26.1)1.98 (0.500 to 22.9)
SecondaryParts 1 and 2: AUClast After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1

AUClast was defined as the area under the plasma or serum concentration-time curve from the time of dosing to the last measurable concentration.

Time frame:
Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1
Reported as:
Mean · hr*ng/mL
Parts 1 and 2: AUClast After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1
hr*ng/mLPart 1: Intermittent Pemigatinib 1 mg QDPart 1: Intermittent Pemigatinib 2 mg QDPart 1: Intermittent Pemigatinib 4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD
Parts 1 and 2: AUClast After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1190 ± NA68.8 ± NA1010 ± NA641 ± 1161140 ± 4981820 ± 12102510 ± 935
SecondaryParts 1 and 2: AUC0-24 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1

AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.

Time frame:
Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1
Reported as:
Mean · hr*ng/mL
Parts 1 and 2: AUC0-24 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1
hr*ng/mLPart 1: Intermittent Pemigatinib 1 mg QDPart 1: Intermittent Pemigatinib 2 mg QDPart 1: Intermittent Pemigatinib 4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD
Parts 1 and 2: AUC0-24 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1191 ± NANA ± NA1010 ± NA644 ± 1151150 ± 4971840 ± 10802850 ± 1050
SecondaryParts 1 and 2: Cmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

Cmax was defined as the maximum observed plasma concentration.

Time frame:
Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Reported as:
Mean · ng/mL
Parts 1 and 2: Cmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
ng/mLPart 1: Intermittent Pemigatinib 1 mg QDPart 1: Intermittent Pemigatinib 2 mg QDPart 1: Intermittent Pemigatinib 4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD
Parts 1 and 2: Cmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)26.2 ± NA22.9 ± NA103 ± NA86.1 ± 38.0196 ± 123271 ± 151449 ± 172
Statistical analysis
  • Part 1: Intermittent Pemigatinib 6 mg QD vs Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD · ANOVA · p = 0.28411-factor ANOVA of log-transformed, dose-normalized data (factor = dose)
  • Part 1: Intermittent Pemigatinib 6 mg QD vs Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD · ANOVA · p = 0.30421-factor ANOVA of log-transformed, dose-normalized data (factor = dose)
  • Part 1: Intermittent Pemigatinib 6 mg QD vs Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD · ANOVA · p = 0.12591-factor ANOVA of log-transformed, dose-normalized data (factor = dose)
  • Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD vs Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD · ANOVA · p = 0.82141-factor ANOVA of log-transformed, dose-normalized data (factor = dose)
  • Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD vs Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD · ANOVA · p = 0.43151-factor ANOVA of log-transformed, dose-normalized data (factor = dose)
  • Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD vs Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD · ANOVA · p = 0.25951-factor ANOVA of log-transformed, dose-normalized data (factor = dose)
SecondaryParts 1 and 2: Tmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

tmax was defined as the time to the maximum observed plasma concentration.

Time frame:
Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Reported as:
Median · hr
Parts 1 and 2: Tmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
hrPart 1: Intermittent Pemigatinib 1 mg QDPart 1: Intermittent Pemigatinib 2 mg QDPart 1: Intermittent Pemigatinib 4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD
Parts 1 and 2: Tmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)1.07 (NA to NA)3.98 (NA to NA)2.02 (NA to NA)1.58 (0.983 to 23.7)1.00 (0.500 to 6.10)1.13 (0.500 to 6.00)1.12 (0.517 to 5.90)
SecondaryParts 1 and 2: t1/2 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

t1/2 was defined as the apparent plasma terminal phase disposition half-life.

Time frame:
Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Reported as:
Mean · hr
Parts 1 and 2: t1/2 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
hrPart 1: Intermittent Pemigatinib 1 mg QDPart 1: Intermittent Pemigatinib 2 mg QDPart 1: Intermittent Pemigatinib 4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD
Parts 1 and 2: t1/2 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)10.9 ± NA18.1 ± NA30.4 ± NA21.0 ± 22.817.2 ± 9.7017.4 ± 9.6413.1 ± 6.01
SecondaryParts 1 and 2: Cmin After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

Cmin was defined as the minimum observed plasma concentration over the dose interval.

Time frame:
Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Reported as:
Mean · ng/mL
Parts 1 and 2: Cmin After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
ng/mLPart 1: Intermittent Pemigatinib 1 mg QDPart 1: Intermittent Pemigatinib 2 mg QDPart 1: Intermittent Pemigatinib 4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD
Parts 1 and 2: Cmin After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)3.24 ± NA7.87 ± NA23.9 ± NA30.0 ± 15.149.9 ± 49.671.7 ± 56.7104 ± 93.3
SecondaryParts 1 and 2: AUC0-24 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.

Time frame:
Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Reported as:
Mean · hr*ng/mL
Parts 1 and 2: AUC0-24 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
hr*ng/mLPart 1: Intermittent Pemigatinib 1 mg QDPart 1: Intermittent Pemigatinib 2 mg QDPart 1: Intermittent Pemigatinib 4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD
Parts 1 and 2: AUC0-24 After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)208 ± NA322 ± NA1380 ± NA1080 ± 3012180 ± 16303010 ± 18904350 ± 1480
Statistical analysis
  • Part 1: Intermittent Pemigatinib 6 mg QD vs Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD · ANOVA · p = 0.85771-factor ANOVA of log-transformed, dose-normalized data (factor = dose)
  • Part 1: Intermittent Pemigatinib 6 mg QD vs Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD · ANOVA · p = 0.72381-factor ANOVA of log-transformed, dose-normalized data (factor = dose)
  • Part 1: Intermittent Pemigatinib 6 mg QD vs Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD · ANOVA · p = 0.59231-factor ANOVA of log-transformed, dose-normalized data (factor = dose)
  • Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD vs Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD · ANOVA · p = 0.76341-factor ANOVA of log-transformed, dose-normalized data (factor = dose)
  • Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD vs Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD · ANOVA · p = 0.57491-factor ANOVA of log-transformed, dose-normalized data (factor = dose)
  • Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD vs Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD · ANOVA · p = 0.68771-factor ANOVA of log-transformed, dose-normalized data (factor = dose)
SecondaryParts 1 and 2: CL/F After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

CL/F was defined as the apparent oral dose clearance.

Time frame:
Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Reported as:
Mean · Liters per hr (L/hr)
Parts 1 and 2: CL/F After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
Liters per hr (L/hr)Part 1: Intermittent Pemigatinib 1 mg QDPart 1: Intermittent Pemigatinib 2 mg QDPart 1: Intermittent Pemigatinib 4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD
Parts 1 and 2: CL/F After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)9.86 ± NA12.8 ± NA5.93 ± NA12.0 ± 3.1415.7 ± 17.711.9 ± 5.7210.3 ± 3.01
SecondaryParts 1 and 2: Vz/F After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

Vz/F was defined as the apparent volume of distribution.

Time frame:
Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Reported as:
Mean · Liters
Parts 1 and 2: Vz/F After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
LitersPart 1: Intermittent Pemigatinib 1 mg QDPart 1: Intermittent Pemigatinib 2 mg QDPart 1: Intermittent Pemigatinib 4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD
Parts 1 and 2: Vz/F After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)156 ± NA334 ± NA260 ± NA301 ± 241246 ± 76.1274 ± 165180 ± 49.1
SecondaryParts 1 and 2: Accumulation Ratio After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)

The accumulation ratio was defined as the ratio of the accumulation of a drug under steady-state conditions as compared to a single dose.

Time frame:
Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Reported as:
Mean · ratio
Parts 1 and 2: Accumulation Ratio After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)
ratioPart 1: Intermittent Pemigatinib 1 mg QDPart 1: Intermittent Pemigatinib 2 mg QDPart 1: Intermittent Pemigatinib 4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QDParts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD
Parts 1 and 2: Accumulation Ratio After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)1.09 ± NA1.64 ± NA1.36 ± NA1.67 ± 0.2641.71 ± 0.5341.69 ± 0.5381.76 ± 0.476
SecondaryParts 1 and 2: Cmax Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States

Cmax was defined as the maximum observed plasma concentration.

Time frame:
Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14
Reported as:
Mean · ng/mL
Parts 1 and 2: Cmax Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States
ng/mLPart 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, FastedPart 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed
Parts 1 and 2: Cmax Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States215 ± 86.5179 ± 82.8
Statistical analysis
  • Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fasted vs Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed · ANOVA · p = 0.143crossover ANOVA of log-transformed data
SecondaryParts 1 and 2: Tmax Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States

tmax was defined as the time to the maximum observed plasma concentration.

Time frame:
Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14
Reported as:
Median · hr
Parts 1 and 2: Tmax Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States
hrPart 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, FastedPart 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed
Parts 1 and 2: Tmax Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States1.58 (0.500 to 5.78)4.02 (1.00 to 7.58)
Statistical analysis
  • Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fasted vs Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed · ANOVA · p = 0.0013crossover ANOVA of log-transformed data
SecondaryParts 1 and 2: t1/2 Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States

t1/2 was defined as the apparent plasma terminal phase disposition half-life.

Time frame:
Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14
Reported as:
Mean · hr
Parts 1 and 2: t1/2 Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States
hrPart 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, FastedPart 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed
Parts 1 and 2: t1/2 Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States19.2 ± 10.523.8 ± 17.5
Statistical analysis
  • Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fasted vs Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed · ANOVA · p = 0.319crossover ANOVA of log-transformed data
SecondaryParts 1 and 2: Cmin Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States

Cmin was defined as the minimum observed plasma concentration over the dose interval.

Time frame:
Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14
Reported as:
Mean · ng/mL
Parts 1 and 2: Cmin Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States
ng/mLPart 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, FastedPart 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed
Parts 1 and 2: Cmin Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States61.1 ± 33.565.7 ± 34.7
Statistical analysis
  • Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fasted vs Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed · ANOVA · p = 0.128crossover ANOVA of log-transformed data
SecondaryParts 1 and 2: AUC0-24 Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States

AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.

Time frame:
Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14
Reported as:
Mean · hr*ng/mL
Parts 1 and 2: AUC0-24 Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States
hr*ng/mLPart 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, FastedPart 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed
Parts 1 and 2: AUC0-24 Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States2580 ± 9992910 ± 1310
Statistical analysis
  • Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fasted vs Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed · ANOVA · p = 0.305crossover ANOVA of log-transformed data
SecondaryParts 1 and 2: CL/F Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States

CL/F was defined as the apparent oral dose clearance.

Time frame:
Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14
Reported as:
Mean · L/hr
Parts 1 and 2: CL/F Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States
L/hrPart 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, FastedPart 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed
Parts 1 and 2: CL/F Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States12.4 ± 4.9411.3 ± 4.87
Statistical analysis
  • Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fasted vs Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed · ANOVA · p = 0.305crossover ANOVA of log-transformed data
SecondaryParts 1 and 2: Vz/F Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States

Vz/F was defined as the apparent volume of distribution.

Time frame:
Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14
Reported as:
Mean · Liters
Parts 1 and 2: Vz/F Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States
LitersPart 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, FastedPart 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed
Parts 1 and 2: Vz/F Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States307 ± 139364 ± 262
Statistical analysis
  • Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fasted vs Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed · ANOVA · p = 0.772crossover ANOVA of log-transformed data
SecondaryPart 3: Cmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1

Cmax was defined as the maximum observed plasma concentration.

Time frame:
predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 1
Reported as:
Mean · ng/mL
Part 3: Cmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1
ng/mLPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mg
Part 3: Cmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1137 ± 65.7199 ± 99.6234 ± 84.1214 ± 98.2259 ± 55.4
SecondaryPart 3: Tmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1

tmax was defined as the time to the maximum observed plasma concentration.

Time frame:
predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 1
Reported as:
Median · hr
Part 3: Tmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1
hrPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mg
Part 3: Tmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 11.98 (1.00 to 4.00)1.05 (0.500 to 23.4)2.00 (0.500 to 22.6)1.00 (0.500 to 3.98)0.783 (0.500 to 18.6)
SecondaryPart 3: AUClast of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1

AUClast was defined as the area under the plasma or serum concentration-time curve from the time of dosing to the last measurable concentration.

Time frame:
predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 1
Reported as:
Mean · hr*ng/mL
Part 3: AUClast of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1
hr*ng/mLPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mg
Part 3: AUClast of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 11480 ± 5871880 ± 8212890 ± 10101890 ± 4912040 ± 513
SecondaryPart 3: AUC0-24 of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1

AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.

Time frame:
predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 1
Reported as:
Mean · hr*ng/mL
Part 3: AUC0-24 of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 1
hr*ng/mLPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mg
Part 3: AUC0-24 of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 11550 ± 5521910 ± 8382920 ± 10701890 ± 4711890 ± 269
SecondaryPart 3: Cmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

Cmax was defined as the maximum observed plasma concentration.

Time frame:
predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Reported as:
Mean · ng/mL
Part 3: Cmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)
ng/mLPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mg
Part 3: Cmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)166 ± 52.1255 ± 119214 ± 203231 ± 99.4404 ± 41.7
SecondaryPart 3: Tmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

tmax was defined as the time to the maximum observed plasma concentration.

Time frame:
predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Reported as:
Median · hr
Part 3: Tmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)
hrPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mg
Part 3: Tmax of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)5.78 (1.25 to 6.08)1.08 (0.500 to 7.98)1.50 (0.950 to 4.00)1.90 (0.500 to 2.08)0.583 (0.500 to 1.07)
SecondaryPart 3: t1/2 of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

t1/2 was defined as the apparent plasma terminal phase disposition half-life.

Time frame:
predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Reported as:
Mean · hr
Part 3: t1/2 of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)
hrPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mg
Part 3: t1/2 of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)15.3 ± 0.20717.0 ± 6.9010.6 ± 3.2914.7 ± 6.4315.3 ± 2.64
SecondaryPart 3: Cmin of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

Cmin was defined as the minimum observed plasma concentration over the dose interval.

Time frame:
predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Reported as:
Mean · ng/mL
Part 3: Cmin of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)
ng/mLPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mg
Part 3: Cmin of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)58.0 ± 31.656.6 ± 31.348.5 ± 57.863.1 ± 32.464.2 ± 25.8
SecondaryPart 3: AUC0-24 of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

AUC0-24 was defined as the area under the plasma or serum concentration-time curve from time 0 to 24 hours post-dose.

Time frame:
predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Reported as:
Mean · hr*ng/mL
Part 3: AUC0-24 of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)
hr*ng/mLPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mg
Part 3: AUC0-24 of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)2400 ± 6282400 ± 9671650 ± 10602910 ± 13903440 ± 672
SecondaryPart 3: CL/F of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

CL/F was defined as the apparent oral dose clearance.

Time frame:
predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Reported as:
Mean · L/hr
Part 3: CL/F of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)
L/hrPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mg
Part 3: CL/F of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)8.03 ± 1.8913.4 ± 5.4624.5 ± 17.712.7 ± 9.038.26 ± 1.39
SecondaryPart 3: Vz/F of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

Vz/F was defined as the apparent volume of distribution.

Time frame:
predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Reported as:
Mean · Liters
Part 3: Vz/F of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)
LitersPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mg
Part 3: Vz/F of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)177 ± 39.8303 ± 136376 ± 261227 ± 82.2182 ± 43.2
SecondaryPart 3: Accumulation Ratio of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)

The accumulation ratio was defined as the ratio of the accumulation of a drug under steady-state conditions as compared to a single dose.

Time frame:
predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14
Reported as:
Mean · ratio
Part 3: Accumulation Ratio of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)
ratioPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mg
Part 3: Accumulation Ratio of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)1.65 ± 0.5011.53 ± 0.3810.604 ± 0.2651.52 ± 0.7721.90 ± 0.432

Adverse events

Collected over up to 869 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Intermittent Pemigatinib 1/2/4 mg QD3/3 (100%)1/3 (33.3%)3/3 (100%)
Part 1: Intermittent Pemigatinib 6 mg QD2/4 (50%)0/4 (0%)3/4 (75%)
Parts 1 and 2: Intermittent Pemigatinib 9 mg QD6/7 (85.7%)3/7 (42.9%)7/7 (100%)
Parts 1 and 2: Intermittent Pemigatinib 13.5 mg QD37/50 (74%)21/50 (42%)50/50 (100%)
Part 1: Intermittent Pemigatinib 20 mg QD6/6 (100%)3/6 (50%)6/6 (100%)
Parts 1 and 2: Continuous Pemigatinib 9 mg QD10/14 (71.4%)6/14 (42.9%)14/14 (100%)
Parts 1 and 2: Continuous Pemigatinib 13.5 mg QD21/30 (70%)14/30 (46.7%)30/30 (100%)
Parts 1 and 2: Continuous Pemigatinib 20 mg QD10/15 (66.7%)7/15 (46.7%)15/15 (100%)
Part 1: Continuous Pemigatinib 7.5 mg BID4/4 (100%)2/4 (50%)4/4 (100%)
Part 1: Continuous Pemigatinib 10 mg BID2/3 (66.7%)2/3 (66.7%)3/3 (100%)
Part 3: Gem/Cis/Intermittent Pemigatinib 9 mg1/1 (100%)1/1 (100%)1/1 (100%)
Part 3: Gem/Cis/Intermittent Pemigatinib 13.5 mg7/7 (100%)3/7 (42.9%)7/7 (100%)
Part 3: Tras/Intermittent Pemigatinib 13.5 mg5/6 (83.3%)0/6 (0%)6/6 (100%)
Part 3: Doc/Intermittent Pemigatinib 13.5 mg5/7 (71.4%)6/7 (85.7%)7/7 (100%)
Part 3: Pem/Intermittent Pemigatinib 9 mg3/3 (100%)1/3 (33.3%)3/3 (100%)
Part 3: Pem/Intermittent Pemigatinib 13.5 mg9/14 (64.3%)7/14 (50%)14/14 (100%)
Part 3: Pem/Continuous Pemigatinib 13.5 mg6/9 (66.7%)3/9 (33.3%)9/9 (100%)
Part 3: Ref/Continuous Pemigatinib 9 mg6/7 (85.7%)4/7 (57.1%)7/7 (100%)
Part 3: Ref/Continuous Pemigatinib 13.5 mg3/9 (33.3%)5/9 (55.6%)9/9 (100%)
Part 3: Ref/Continuous Pemigatinib 20 mg0/2 (0%)2/2 (100%)2/2 (100%)
Most frequent serious events
Showing 10 of 112
Most frequent serious events
EventPart 1: Intermittent Pemigatinib 1/2/4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDParts 1 and 2: Intermittent Pemigatinib 9 mg QDParts 1 and 2: Intermittent Pemigatinib 13.5 mg QDPart 1: Intermittent Pemigatinib 20 mg QDParts 1 and 2: Continuous Pemigatinib 9 mg QDParts 1 and 2: Continuous Pemigatinib 13.5 mg QDParts 1 and 2: Continuous Pemigatinib 20 mg QDPart 1: Continuous Pemigatinib 7.5 mg BIDPart 1: Continuous Pemigatinib 10 mg BIDPart 3: Gem/Cis/Intermittent Pemigatinib 9 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 9 mgPart 3: Ref/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 20 mg
Acute kidney injuryRenal and urinary disorders0/30/40/70/500/61/143/300/150/40/30/11/70/61/70/30/140/91/70/92/2
ConstipationGastrointestinal disorders0/30/41/70/500/60/140/301/150/40/31/10/70/60/70/30/140/90/70/90/2
Febrile neutropeniaBlood and lymphatic system disorders0/30/40/70/500/60/140/300/150/40/31/10/70/60/70/30/140/90/70/90/2
AnaemiaBlood and lymphatic system disorders0/30/40/71/500/60/140/301/150/40/30/10/70/61/70/31/140/90/71/91/2
FatigueGeneral disorders0/30/40/71/500/60/143/301/150/40/30/10/70/61/70/30/140/91/70/91/2
PneumoniaInfections and infestations0/30/42/72/501/61/141/301/152/40/30/10/70/60/70/30/141/90/71/90/2
Completed suicidePsychiatric disorders0/30/40/70/500/60/140/300/150/40/30/10/70/60/71/30/140/90/70/90/2
Depressed level of consciousnessNervous system disorders1/30/40/70/500/60/140/300/150/40/30/10/70/60/70/30/140/90/70/90/2
Disease progressionGeneral disorders1/30/40/71/500/60/141/301/150/41/30/11/70/60/70/30/140/90/71/90/2
HypertensionVascular disorders0/30/40/70/500/60/140/300/150/41/30/10/70/60/70/31/140/90/70/90/2
Most frequent other events
Showing 10 of 385
Most frequent other events
EventPart 1: Intermittent Pemigatinib 1/2/4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDParts 1 and 2: Intermittent Pemigatinib 9 mg QDParts 1 and 2: Intermittent Pemigatinib 13.5 mg QDPart 1: Intermittent Pemigatinib 20 mg QDParts 1 and 2: Continuous Pemigatinib 9 mg QDParts 1 and 2: Continuous Pemigatinib 13.5 mg QDParts 1 and 2: Continuous Pemigatinib 20 mg QDPart 1: Continuous Pemigatinib 7.5 mg BIDPart 1: Continuous Pemigatinib 10 mg BIDPart 3: Gem/Cis/Intermittent Pemigatinib 9 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 9 mgPart 3: Ref/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 20 mg
Abdominal painGastrointestinal disorders0/30/41/710/501/62/146/302/150/40/31/11/70/61/70/32/142/90/71/90/2
AlopeciaSkin and subcutaneous tissue disorders0/30/43/715/501/66/1411/305/151/42/30/11/75/63/70/36/145/91/73/92/2
AnaemiaBlood and lymphatic system disorders1/30/41/710/502/66/146/304/152/41/31/17/72/63/71/37/143/92/70/91/2
Blood creatinine increasedInvestigations0/30/41/72/500/60/1411/304/151/40/31/14/71/61/71/34/141/91/72/92/2
DehydrationMetabolism and nutrition disorders1/31/40/76/501/61/144/304/154/41/31/11/70/64/71/32/141/93/73/91/2
Dry mouthGastrointestinal disorders0/31/43/717/502/65/1413/308/152/43/31/12/74/61/70/34/145/94/73/92/2
DysgeusiaNervous system disorders1/30/41/75/501/62/149/304/154/42/30/12/70/63/70/32/141/91/72/90/2
HyperphosphataemiaMetabolism and nutrition disorders0/31/44/739/504/68/1428/3013/154/43/31/13/75/66/73/311/145/94/75/92/2
HypoalbuminaemiaMetabolism and nutrition disorders0/30/40/73/500/60/142/301/150/40/31/10/71/61/71/32/140/90/70/90/2
HypokalaemiaMetabolism and nutrition disorders1/31/42/73/500/62/141/302/151/41/31/12/70/60/70/33/140/92/71/90/2

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part 1: Intermittent Pemigatinib 1/2/4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDPart 1: Intermittent Pemigatinib 9 mg QDPart 1: Intermittent Pemigatinib 13.5 mg QDPart 1: Intermittent Pemigatinib 20 mg QDPart 1: Continuous Pemigatinib 9 mg QDPart 1: Continuous Pemigatinib 13.5 mg QDPart 1: Continuous Pemigatinib 20 mg QDPart 1: Continuous Pemigatinib 7.5 mg BIDPart 1: Continuous Pemigatinib 10 mg BIDPart 2: Intermittent Pemigatinib 9 mg QDPart 2: Intermittent Pemigatinib 13.5 mg QDPart 2: Continuous Pemigatinib 9 mg QDPart 2: Continuous Pemigatinib 13.5 mg QDPart 2: Continuous Pemigatinib 20 mg QDPart 3: Gem/Cis/Intermittent Pemigatinib 9 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 9 mgPart 3: Ref/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 20 mgTotal
Mean60.7 ± 11.2445.5 ± 17.3156.3 ± 4.9359.0 ± 14.7956.2 ± 11.8957.9 ± 15.7061.2 ± 16.8856.3 ± 15.1966.8 ± 4.5768.7 ± 15.8950.3 ± 12.3957.7 ± 11.8163.8 ± 10.6957.4 ± 13.7858.3 ± 8.8061.0 ± NA54.1 ± 10.4347.8 ± 14.4462.4 ± 9.1655.0 ± 15.7264.7 ± 10.5061.8 ± 10.8963.4 ± 11.4366.9 ± 8.8068.0 ± 7.0759.0 ± 12.61
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Intermittent Pemigatinib 1/2/4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDPart 1: Intermittent Pemigatinib 9 mg QDPart 1: Intermittent Pemigatinib 13.5 mg QDPart 1: Intermittent Pemigatinib 20 mg QDPart 1: Continuous Pemigatinib 9 mg QDPart 1: Continuous Pemigatinib 13.5 mg QDPart 1: Continuous Pemigatinib 20 mg QDPart 1: Continuous Pemigatinib 7.5 mg BIDPart 1: Continuous Pemigatinib 10 mg BIDPart 2: Intermittent Pemigatinib 9 mg QDPart 2: Intermittent Pemigatinib 13.5 mg QDPart 2: Continuous Pemigatinib 9 mg QDPart 2: Continuous Pemigatinib 13.5 mg QDPart 2: Continuous Pemigatinib 20 mg QDPart 3: Gem/Cis/Intermittent Pemigatinib 9 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 9 mgPart 3: Ref/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 20 mgTotal
Female222336560232751050343153751113
Male12133353411170101142429604188
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Intermittent Pemigatinib 1/2/4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDPart 1: Intermittent Pemigatinib 9 mg QDPart 1: Intermittent Pemigatinib 13.5 mg QDPart 1: Intermittent Pemigatinib 20 mg QDPart 1: Continuous Pemigatinib 9 mg QDPart 1: Continuous Pemigatinib 13.5 mg QDPart 1: Continuous Pemigatinib 20 mg QDPart 1: Continuous Pemigatinib 7.5 mg BIDPart 1: Continuous Pemigatinib 10 mg BIDPart 2: Intermittent Pemigatinib 9 mg QDPart 2: Intermittent Pemigatinib 13.5 mg QDPart 2: Continuous Pemigatinib 9 mg QDPart 2: Continuous Pemigatinib 13.5 mg QDPart 2: Continuous Pemigatinib 20 mg QDPart 3: Gem/Cis/Intermittent Pemigatinib 9 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 9 mgPart 3: Ref/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 20 mgTotal
Hispanic or Latino000021100014040000001100015
Not Hispanic or Latino2336489943339516617673138791182
Unknown or Not Reported11000000000100000000000014
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: Intermittent Pemigatinib 1/2/4 mg QDPart 1: Intermittent Pemigatinib 6 mg QDPart 1: Intermittent Pemigatinib 9 mg QDPart 1: Intermittent Pemigatinib 13.5 mg QDPart 1: Intermittent Pemigatinib 20 mg QDPart 1: Continuous Pemigatinib 9 mg QDPart 1: Continuous Pemigatinib 13.5 mg QDPart 1: Continuous Pemigatinib 20 mg QDPart 1: Continuous Pemigatinib 7.5 mg BIDPart 1: Continuous Pemigatinib 10 mg BIDPart 2: Intermittent Pemigatinib 9 mg QDPart 2: Intermittent Pemigatinib 13.5 mg QDPart 2: Continuous Pemigatinib 9 mg QDPart 2: Continuous Pemigatinib 13.5 mg QDPart 2: Continuous Pemigatinib 20 mg QDPart 3: Gem/Cis/Intermittent Pemigatinib 9 mgPart 3: Gem/Cis/Intermittent Pemigatinib 13.5 mgPart 3: Tras/Intermittent Pemigatinib 13.5 mgPart 3: Doc/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Intermittent Pemigatinib 9 mgPart 3: Pem/Intermittent Pemigatinib 13.5 mgPart 3: Pem/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 9 mgPart 3: Ref/Continuous Pemigatinib 13.5 mgPart 3: Ref/Continuous Pemigatinib 20 mgTotal
White/Caucasian34265810843337518615662109791178
Black/African-American001010000007000010112000115
Asian00000101000001001000000004
American-Indian/Alaska Native00000000000000000000000000
Native Hawaiian/Pacific Islander00000000000000000000000000
Captured as Other00000000001001000000200004
08

Study locations

20 sites
  • University of Alabama At Birmingham Comprehensive Cancer Center
    Birmingham, Alabama 35205, United States
  • Cedars-Sinai Medical Center
    West Hollywood, California 90048, United States
  • Yale Cancer Center
    New Haven, Connecticut 06510, United States
  • Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Hematology Oncology Associates of the Tr
    Port Saint Lucie, Florida 34952, United States
  • Emory University - Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48109, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • John Theurer Cancer Center, Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Montefiore Medical Center
    Bronx, New York 10461, United States
  • Northwell Health - Monter Cancer Center
    New Hyde Park, New York 11042, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Ohio State University - Wexner Medical Center
    Columbus, Ohio 43210, United States
  • Signal Point Clinical Research Center
    Middletown, Ohio 45042, United States
  • Greenville Health System Cancer Institute
    Greenville, South Carolina 29605, United States
  • Mary Crowley Cancer Research Ctr
    Dallas, Texas 75230, United States
  • Md Anderson Cancer Center
    Houston, Texas 77030, United States
  • South Texas Accelerated Research Therapeutics
    San Antonio, Texas 78229, United States
  • Baylor Scott & White Health
    Temple, Texas 76508, United States
  • The Finsen Centre National Hospital
    Copenhagen, 02100, Denmark
09

References and documents

Publications

  • Subbiah V, Iannotti NO, Gutierrez M, Smith DC, Feliz L, Lihou CF, Tian C, Silverman IM, Ji T, Saleh M. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Ann Oncol. 2022 May;33(5):522-533. doi: 10.1016/j.annonc.2022.02.001. Epub 2022 Feb 14. PubMed 35176457 ↗
  • Gong X, Ji T, Liu X, Chen X, Yeleswaram S. Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies. Pharmacol Res Perspect. 2022 Feb;10(1):e00906. doi: 10.1002/prp2.906. PubMed 34951522 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2015 to primary completion in Dec 2021, 81 months.

Results were first posted in Jan 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2015
First posted
Mar 19, 2015
StartActual
Feb 27, 2015
Primary completionActual
Dec 17, 2021
CompletionActual
Dec 17, 2021
Results first posted
Jan 6, 2023
Last update
Jan 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02393248
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Mar 19, 2015
Start date
Feb 27, 2015
Primary completion
Dec 17, 2021
Completion
Dec 17, 2021
Results posted
Jan 6, 2023
Last update
Jan 6, 2023

Study contacts

Luis Féliz, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemigatinib

Start the discussion